- Trial phase
- Approved
- Time to market
- Already approved and marketed (FDA approved June 2021).
- Why 4/10
- TEMBEXA is already FDA-approved and commercially marketed with no pending regulatory decision (PDUFA, AdComm, or pivotal readout) in the next 12 months. The next catalysts are government contract awards and the mpox trial readout, neither of which is a hard dated binary. Per the rubric, an approved drug with no imminent new regulatory decision scores 3-5.
Watch for additional U.S. government (BARDA/ASPR) contract modifications for TEMBEXA stockpiling, which drive the drug's revenue. The mpox clinical trial in Africa (PANTHER study) could open a larger addressable market if results are positive, but that readout has no firm date yet. EBS reports full-year 2026 results in early 2027, which will show whether TEMBEXA deliveries continue to offset declines in other smallpox MCM products.
Price Chart
Executive Summary
TEMBEXA (brincidofovir) is an FDA-approved oral antiviral for smallpox, cleared in June 2021 under the Animal Rule since human efficacy trials are not feasible for the eradicated disease. Emergent BioSolutions (NYSE: EBS) acquired worldwide rights from Chimerix in September 2022 for $325 million. The drug competes with SIGA Technologies' TPOXX (tecovirimat) in a market driven almost entirely by U.S. and allied government biodefense stockpiling contracts. TEMBEXA is approved for all ages including neonates, a unique label advantage. Emergent has secured multiple government contract modifications totaling over $84 million for TEMBEXA since 2024. However, the drug is a modest part of Emergent's broader portfolio (which includes ACAM2000 vaccine, anthrax products, and naloxone), and the company is under financial strain with Q3 2026 revenue down 52% YoY and a restructuring underway. No near-term binary regulatory catalyst exists for TEMBEXA, making it a steady but unexciting contributor within a challenged company.
How It Works
TEMBEXA is an oral antiviral pill or liquid that stops the smallpox virus from replicating inside human cells. It is a 'prodrug' meaning the body converts it into an active form (cidofovir) after it is swallowed. A lipid (fat) coating helps it get into cells more efficiently and reduces kidney toxicity compared to the older drug cidofovir.
Trial Status
TEMBEXA was approved by the FDA in June 2021 under the Animal Rule, based on efficacy in animal models of smallpox and safety data from human trials in other diseases. The drug is currently being evaluated in a clinical trial for mpox (monkeypox) in Africa, sponsored by PANTHER and the Africa CDC, with Emergent supplying the drug.
The Two-Sided Case
Upcoming Catalysts
- Additional U.S. government (BARDA/ASPR) contract modifications for TEMBEXA stockpiling
- Readout from the PANTHER mpox clinical trial in Africa (no firm date announced)
- Emergent's full-year 2026 earnings report (early 2027) showing TEMBEXA revenue contribution
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Emergent BioSolutions Inc. 8-K EBS ·Originating report